# L. Zeng

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/l-zeng/

## Facts

| Field | Value |
| --- | --- |
| Citations | 107 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 5 |
| i10-index | 4 |
| Last Known Institution | Central South University |
| OpenAlex ID | https://openalex.org/A5100588822 |
| Works | 17 |

## Researcher papers

- [Expression of claudin 10 protein in hepatocellular carcinoma: impact on survival](https://scholariq.org/papers/expression-of-claudin-10-protein-in-hepatocellular-carcinoma-impact-on-survival/)
- [The Incidence and Prognosis Value of Perineural Invasion in Rectal Carcinoma: From Meta-Analyses and Real-World Clinical Pathological Features](https://scholariq.org/papers/the-incidence-and-prognosis-value-of-perineural-invasion-in-rectal-carcinoma/)
- [Daidzein alleviates ethanol-induced acute gastric injury in rats by targeting ESR1 and activating the PI3K/AKT/CREB signaling pathway](https://scholariq.org/papers/daidzein-alleviates-ethanol-induced-acute-gastric-injury-in-rats-by-targeting/)
- [Correlation of quantitative parameters of magnetic resonance perfusion‐weighted imaging with vascular endothelial growth factor, microvessel density and hypoxia‐inducible factor‐1α in nasopharyngeal carcinoma: Evaluation on radiosensitivity study](https://scholariq.org/papers/correlation-of-quantitative-parameters-of-magnetic-resonance-perfusion-weighted/)
- [1160P Efficacy and biomarker identification of neoadjuvant chemo-immunotherapy in potentially resectable non-small cell lung cancer](https://scholariq.org/papers/1160p-efficacy-and-biomarker-identification-of-neoadjuvant-chemo-immunotherapy/)
- [P15.02 Toripalimab and Platinum-Doublet Chemotherapy as Neoadjuvant Therapy for Potentially Resectable Non-Small Cell Lung Cancer](https://scholariq.org/papers/p15-02-toripalimab-and-platinum-doublet-chemotherapy-as-neoadjuvant-therapy-for/)
- [P1.09-02 Midkine Dependent Immunosuppressive Environment in Cerebrospinal Fluid May Promote Leptomeningeal Metastases of EGFR mutant NSCLC](https://scholariq.org/papers/p1-09-02-midkine-dependent-immunosuppressive-environment-in-cerebrospinal-fluid/)
- [P2.14-51 Dual ALK Fusion Partners as Poor Predictive Marker in First Line Crizotinib Treated ALK Rearranged Non-Small Cell Lung Cancer](https://scholariq.org/papers/p2-14-51-dual-alk-fusion-partners-as-poor-predictive-marker-in-first-line/)
- [P116 Real World Data of 1st Line A+T in Advanced EGFR+ NSCLC: Clinical Outcome, PFS Influential Factors and Acquired Resistance](https://scholariq.org/papers/p116-real-world-data-of-1st-line-a-t-in-advanced-egfr-nsclc-clinical-outcome-pfs/)
- [Risk score model with two immune infiltration‑related long non‑coding RNAs to predict prognosis in patients with osteosarcoma](https://scholariq.org/papers/risk-score-model-with-two-immune-infiltration-related-long-non-coding-rnas-to/)
- [P1.01-22 Investigation of Acquired Resistance for EGFR-TKI Plus Bevacizumab as 1st Line Treatment in Patients with EGFR Sensitive Mutant NSCLC](https://scholariq.org/papers/p1-01-22-investigation-of-acquired-resistance-for-egfr-tki-plus-bevacizumab-as/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)
- [Radiomics and Machine Learning in Medical Imaging](https://scholariq.org/topics/radiomics-and-machine-learning-in-medical-imaging/)

## Researcher university

- [Central South University](https://scholariq.org/institutions/central-south-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.